EFFECTS OF SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK IN TOPCAT AMERICAS

被引：0
|
作者：
Chatur, Safia [1 ]
Beldhuis, Iris [1 ]
Neuen, Brendon [1 ]
Claggett, Brian [1 ]
Desai, Akshay S. [1 ]
Lewis, Eldrin F. [1 ]
Anand, Inderjit S. [1 ]
Shah, Sanjiv Jayendra [1 ]
Sweitzer, Nancy K. [1 ]
Fang, James C. [1 ]
Pitt, Bertram [1 ]
Pfeffer, Marc A. [1 ]
Vaduganathan, Muthiah [1 ]
Solomon, Scott D. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1051-07
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [1] EFFECTS OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK
    Chatur, Safia
    Claggett, Brian
    Mc Causland, Finnian
    Packer, Milton
    Desai, Akshay S.
    Rouleau, Jean L.
    Zile, Michael R.
    Lefkowitz, Martin
    McMurray, John J. V.
    Solomon, Scott D.
    Vaduganathan, Muthiah
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 4605 - 4605
  • [2] Spironolactone, early eGFR dip, and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from TOPCAT Americas
    Beldhuis, I. E. Iris
    Claggett, B. L.
    Neuen, B. L.
    Chatur, S.
    Mc Clausland, F. R.
    Voors, A. A.
    Desai, A. S.
    Lewis, E. F.
    Pitt, B.
    Pfeffer, M. A.
    Solomon, S. D.
    Vaduganathan, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 584 - 584
  • [3] Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
    Zhou, Hui-min
    Zhan, Rong-jian
    Chen, Xuanyu
    Lin, Yi-fen
    Zhang, Shao-zhao
    Zheng, Huigan
    Wang, Xueqin
    Huang, Meng-ting
    Xu, Chao-guang
    Liao, Xin-xue
    Tian, Ting
    Zhuang, Xiao-dong
    ESC HEART FAILURE, 2023, 10 (01): : 322 - 333
  • [4] Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials
    Inciardi, Riccardo Maria
    Vaduganathan, M.
    Claggett, B.
    Abouezzeddine, O. F.
    Borlaug, B. A.
    Desay, A. S.
    Jhund, P. S.
    Lam, C. S. P.
    Minamisawa, M.
    Redfield, M. M.
    Shah, S. J.
    Fontana, M.
    Mcmurray, J. J. V.
    Solomon, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 67 - 68
  • [5] Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
    Lin, Yifen
    Zhong, Xiangbin
    Liu, Menghui
    Zhang, Shaozhao
    Xiong, Zhenyu
    Huang, Yiquan
    Fan, Yongqiang
    Xu, Xingfeng
    Guo, Yue
    Li, Yuqi
    Sun, Xiuting
    Zhou, Huimin
    Yang, Daya
    Ye, Xiaomin
    Liao, Xinxue
    Zhuang, Xiaodong
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (02) : 323 - 331
  • [6] Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
    Yifen Lin
    Xiangbin Zhong
    Menghui Liu
    Shaozhao Zhang
    Zhenyu Xiong
    Yiquan Huang
    Yongqiang Fan
    Xingfeng Xu
    Yue Guo
    Yuqi Li
    Xiuting Sun
    Huimin Zhou
    Daya Yang
    Xiaomin Ye
    Xinxue Liao
    Xiaodong Zhuang
    Cardiovascular Drugs and Therapy, 2022, 36 : 323 - 331
  • [7] Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter, Sumeet S.
    Shah, Sanjiv J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (11)
  • [8] Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas
    Kao, D. P. David Peter
    Flint, K. M.
    Merrill, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 530 - 531
  • [9] Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Sumeet S. Mitter
    Sanjiv J. Shah
    Current Atherosclerosis Reports, 2015, 17
  • [10] The utility of the MAGGIC heart failure risk score in predicting response to spironolactone: validation and results from the TOPCAT trial
    Silverman, D. Daniel
    Baldridge, A.
    Shah, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 398 - 399
12345